Linear Growth of Children With Congenital Adrenal Hyperplasia

Status Not yet recruiting

Clinical Trial Summary

The congenital adrenal hyperplasias (CAHs) comprise a family of autosomal recessive disorders that disrupt adrenal steroidogenesis. Three specific enzyme deficiencies are associated with virilization of affected women. The most common form is 21-hydroxylase deficiency (21-OHD) due to mutations in the 21-hydroxylase (CYP21A2) gene. Other virilizing forms include 3b-hydroxysteroid dehydrogenase type 2 (HSD3B2) and 11b-hydroxylase deficiencies associated with mutations in the HSD3B2 and 11b-hydroxylase (CYP11B1) genes, respectively.

Clinical Trial Description

It has been reported that approximately one child in every 18000 born in Great Britain has CAH. In North America, the incidence varies from 1:15000 to 1:16000. The reported rates of CAH have been as high as 1:280 among the Yupik people of Alaska and 1:2100 on the French island of Réunion in Indian ocean; both of these populations are geographically isolated. The reported incidence of CAH in the two Brazilian states that have routinely included CAH in their public newborn screening programs is 1:11655 in the South (Santa Catarina) and 1:10325 in Midwest (Goiás).

Salt-losing CAH accounts for about three quartes of cases reported and non-salt losing CAH for one quarter. Non-classic is more common ;Estimated as 1 in 1000-2000 in white populations. It is more frequent in certain ethnic groups, such as the Ashkenazi Jewish population. The mild non-classic form is a common cause of hyperandrogenism.

Treatment of classic 21-OHD consists of replacement doses of gluco- (GC) and mineralocorticoids aiming to reduce excess androgen, and to allow adequate linear growth. However, several series report that growth in these children is below expectation, as compared with both the reference population and the target height (TH).

The reasons for the inadequate growth and impairment of the final height (FH) are not completely understood. A major cause is the difficulty in accomplishing a fine balance between inhibition of excess androgen production which accelerates bone maturation and adequate GC replacement itself which even at slightly supraphysiologic doses can be deleterious to growth. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04087148
Study type	Observational
Source	Assiut University
Contact	Hanaa Abdellatef Mohammad, Professor of pediatrics
Phone	01064747613
Email	hae50@aun.edu.eg
Status	Not yet recruiting
Phase
Start date	September 24, 2019
Completion date	October 24, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03687242` - Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia	Phase 2
Active, not recruiting	`NCT04544410` - A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH	Phase 2
Completed	`NCT03162159` - Adult Height Prediction in Congenital Adrenal Hyperplasia
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Enrolling by invitation	`NCT05162950` - Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH
Withdrawn	`NCT03532022` - Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy	Phase 3
Recruiting	`NCT02795871` - Prenatal Dex Study	N/A
Completed	`NCT02934399` - Dynamic Hormone Diagnostics in Endocrine Disease
Recruiting	`NCT04903587` - Gonadal Changes In Congenital Adrenal Hyperplasia Patients
Not yet recruiting	`NCT04536662` - Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency	Phase 4
Recruiting	`NCT04463316` - GROWing Up With Rare GENEtic Syndromes
Active, not recruiting	`NCT04490915` - Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia	Phase 3
Completed	`NCT01807364` - Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia	N/A
Completed	`NCT02804178` - A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia	Phase 2
Completed	`NCT03019614` - An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone	Phase 1
Not yet recruiting	`NCT04293133` - Final Height in Patients With CAH
Recruiting	`NCT03897504` - Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty	N/A
Recruiting	`NCT05663320` - A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia	N/A
Active, not recruiting	`NCT04806451` - Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)	Phase 3
Completed	`NCT01875640` - Decision Support for Parents Receiving Information About Child's Rare Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.